Laddar...
Novel Therapies in Advanced Renal Cell Carcinoma: Management of Adverse Events From Sorafenib and Sunitinib
INTRODUCTION: Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects. METHODS: Selective review in Medline and the data base of...
Sparad:
| Huvudupphovsmän: | , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Deutscher Arzte Verlag
2008
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2696772/ https://ncbi.nlm.nih.gov/pubmed/19629201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3238/arztebl.2008.0232 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|